and its pharmaceutically acceptable salt.

54. (New) The compound of claim 53, wherein the compound is comprised of a mixture of the E and Z isomers.

55. (New) The compound of claim 54, wherein the compound is the E isomer having the structure:



and its pharmaceutically acceptable salt.

56. (New) The compound of claim 54, wherein the compound is the Z isomer having the structure:



and its pharmaceutically acceptable salt.

57. (New) A composition comprising the compound of any of claims 53 to 56 and a carrier.

58. (New) A composition according to claim 57, wherein the carrier is a pharmaceutically acceptable carrier.

59. (New) A method for inhibiting the proliferation of a pathological cell *in vitro*, wherein thymidylate synthase is overexpressed in the cell, comprising contacting the cell with an effective amount of the compound according to any of claims 53 to 56.

60. (New) A method according to claim 59, wherein the pathological cell is a colon cancer cell, a breast cancer cell, a gastric cancer cell, a head and neck cancer cell, a liver cancer cell, or a pancreatic cancer cell.

61. (New) A method according to claim 59, wherein the pathological cell is a colon cancer cell.

62. (New) Use of the compound according to any of claims 53 to 56 for the manufacture of a medicament for use in the treatment of a pathology characterized by pathological cells that overexpress thymidylate synthase.

REMARKS

Applicants respectfully request consideration and entry of the preceding amendments. Support for the aforementioned new claims is located in the claims as filed and throughout the specification. Specifically, examples of support for the claimed compounds are found at page 70, lines 10 through 22 and at page 31, the first and third compounds. Specific examples of support for the types of cancer cells which the compounds inhibit is found at page 10, lines 13 and page 66, lines 1 to 33. Support for the *in vitro* use of the claimed compounds for inhibition of proliferation of pathological cells is found at page 35, lines 25 to 27 and page 67, lines 14 to 20. Support for the use of carriers and pharmaceutical carriers in combination with the claimed compounds is found at page 9, lines 19 to 22, page 10, lines 1 to 7, and page 38, lines 8 to 13. Support for the use of the claimed compounds as medicaments is found at, for example, page 5, lines 20 to 22, and page 36, line 30 to page 41, line 20. An issue of new matter is not raised by entry of these amendments.